Kiniksa Pharmaceuticals International, plc officer Ross Moat filed a Form 144 notice of proposed sale of 103,585 Class A ordinary shares on October 30, 2026, disclosing an aggregate market value of $9,753,812.00 and reliance on a Rule 10b5-1 plan adopted on July 29, 2026.

Key Highlights

  • Proposed seller: Ross Moat, listed as an officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA).
  • Shares to be sold: 103,585 Class A ordinary shares with a reported aggregate market value of $9,753,812.00.
  • Shares outstanding: 48,836,965 Class A ordinary shares outstanding at the time of the notice.
  • Rule 10b5-1 plan: The notice states a plan adoption date of July 29, 2026, indicating reliance on Rule 10b5-1 under the Exchange Act.
  • Acquisition sources: Shares were acquired through two restricted stock lapses (1,735 shares on April 1, 2026, and 4,278 shares on September 1, 2026) and a cashless employee stock option exercise of 97,572 shares on October 30, 2026, all from Kiniksa Pharmaceuticals, Ltd. via equity compensation or broker payment for cashless exercise.
  • Broker: Charles Schwab and Co., Inc., Westlake, TX, is named as the executing broker.
  • Prior three-month sales: The filing reports nothing to report for securities sold during the past three months.

Ross Moat's Proposed Share Sale: Acquisition Details and Plan Structure

According to the Form 144 filed with the SEC on October 30, 2026, Ross Moat, an officer of Kiniksa Pharmaceuticals International, plc, intends to sell 103,585 Class A ordinary shares. The filing identifies the exchange as NASDAQ and names Charles Schwab and Co., Inc. as the broker through which the shares are proposed to be sold. The filing notes that "the shares reported on this filing may be sold over various dates."

The filing discloses three separate acquisition transactions as the source of the shares to be sold. A restricted stock lapse of 1,735 shares occurred on April 1, 2026, and a second restricted stock lapse of 4,278 shares occurred on September 1, 2026, both acquired from Kiniksa Pharmaceuticals, Ltd. via equity compensation. The largest tranche, 97,572 shares, was acquired on October 30, 2026, through an employee stock option exercise, with broker payment noted as the nature of payment for that cashless exercise, also from Kiniksa Pharmaceuticals, Ltd.

The notice indicates that Moat adopted a written trading plan under Rule 10b5-1 on July 29, 2026. By signing the form, the filing states, the filer "represents that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The filing reports no sales of issuer securities by Moat during the three months preceding the notice date.

What Was Disclosed

Ross Moat, an officer of Kiniksa Pharmaceuticals International, plc, filed a Form 144 on October 30, 2026, proposing to sell 103,585 Class A ordinary shares with a stated aggregate market value of $9,753,812.00, pursuant to a Rule 10b5-1 plan adopted July 29, 2026.